Has Bryan Johnson confirmed using all of these drugs publicly?

Yes. Johnson publishes his full protocol through blueprint.bryanjohnson.com and has discussed individual compounds including rapamycin, acarbose, NMN, testosterone, and specific peptides in public interviews and social media posts. He disclosed discontinuing rapamycin in early 2024.

Is rapamycin FDA-approved for longevity?

No. Rapamycin (sirolimus) is FDA-approved only as an immunosuppressant for organ transplant recipients and for certain rare conditions. Its use for longevity is off-label, based on animal data showing lifespan extension. No completed human trial has tested rapamycin for lifespan extension.

Can I replicate the Blueprint protocol without Johnson's budget?

The compounds are mostly accessible, but the monitoring infrastructure is not. Johnson's value is in the data feedback loop: frequent labs, imaging, and physician review that allow him to adjust or discontinue drugs based on response. Without that monitoring layer, patients are taking the same drugs with far less safety oversight.

What is the strongest evidence among the drugs Johnson uses?

Acarbose has the most strong animal lifespan data through the NIA's Interventions Testing Program. Testosterone replacement for documented hypogonadism has strong human efficacy and safety data from the TRAVERSE trial. The peptides and NMN have the weakest clinical evidence bases.

Why did Bryan Johnson stop taking rapamycin?

He publicly stated that his biological-age clock data showed the drug was not producing the expected age-reversal signal. Whether this reflects a true failure of rapamycin or a limitation of current epigenetic clocks is an open question in the field.

The Medical Takeaways from Bryan Johnson's Longevity Story

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Celebrity: Bryan Johnson, tech entrepreneur and founder of the Don't Die movement
Drug family: Longevity (rapamycin, NAD+ precursors, acarbose, testosterone, peptides)
Status: Confirmed. Johnson publishes his full protocol, biomarker panels, and supplement stack publicly through blueprint.bryanjohnson.com
Key clinical takeaway: Even with unlimited resources and daily physician oversight, longevity compounds produce mixed, sometimes contradictory biomarker signals that require ongoing reassessment

The Public Record: What Bryan Johnson Has Confirmed

Bryan Johnson, the 48-year-old founder of Braintree (sold to PayPal for $800 million), launched Project Blueprint in 2021 as a systematic attempt to reverse biological aging. He has publicly confirmed spending over $2 million annually on the protocol, which he documents with unusual transparency through his website, YouTube channel, and social media accounts.

His published daily regimen has included over 200 supplements and interventions. The pharmacologically significant compounds Johnson has confirmed using include rapamycin (an mTOR inhibitor), acarbose (an alpha-glucosidase inhibitor), NMN (a NAD+ precursor), testosterone therapy, and several peptides including BPC-157, GHK-Cu, and hexarelin. He tracks results through frequent blood panels, organ-specific imaging, and biological-age testing.

In early 2024, Johnson publicly announced he was discontinuing rapamycin. He cited data from his own biological-age clocks suggesting the drug was not producing the age-reversal signal he expected. This disclosure, made through his social channels and covered by outlets including Bloomberg and WIRED, marked a rare public case of a longevity-protocol adherent abandoning a cornerstone compound based on personal biomarker data.

Rapamycin: The Drug He Stopped Taking

Rapamycin (sirolimus) was originally approved by the FDA as an immunosuppressant for organ transplant recipients. Its longevity relevance stems from animal studies showing that mTOR pathway inhibition extends lifespan in mice by 9% to 14%, with the effect replicated across multiple genetic backgrounds.

Johnson used rapamycin at a low, intermittent dose, a protocol common in the longevity medicine community but not validated by any completed human lifespan trial. The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial and the RAPAMYCIN trial (NCT04488601) are still generating data, and no phase III trial has tested rapamycin for human lifespan extension.

What his discontinuation actually tells us. Johnson's biological-age clocks, likely epigenetic clocks such as Horvath or GrimAge, showed stalling or regression. This raises a question the longevity field has not resolved: do current epigenetic clocks reliably detect the effects of mTOR inhibition? The answer is genuinely unknown. Johnson's decision to stop was rational given his framework, but it does not prove rapamycin failed. It may instead reveal the limits of the measurement tools.

Side-effect realities. Even at low doses (typically 3 to 6 mg weekly in longevity contexts), rapamycin carries documented risks: mouth ulcers, impaired wound healing, lipid elevations, and dose-dependent immunosuppression. Johnson's protocol included frequent lab monitoring to catch these signals early, a luxury most patients lack.

Acarbose: The Quieter Compound

Acarbose, an FDA-approved alpha-glucosidase inhibitor prescribed for type 2 diabetes, appeared in Johnson's protocol for its glucose-flattening properties. The drug slows carbohydrate digestion, reducing postprandial glucose spikes.

Its inclusion in a longevity stack draws from the National Institute on Aging's Interventions Testing Program (ITP), where acarbose extended median lifespan in male mice by 22% and by 5% in females. This sex-dependent effect has not been explained, and no human longevity trial for acarbose exists.

For non-celebrity patients, acarbose is inexpensive, generic, and well-studied for safety. The primary side effects are gastrointestinal: bloating, flatulence, and diarrhea, particularly during the first weeks of use. These are predictable and dose-related. Clinically, it remains a reasonable tool for glucose management, though its longevity benefit in humans is entirely extrapolated from rodent data.

NAD+ Precursors: NMN in the Johnson Protocol

Johnson has publicly used NMN (nicotinamide mononucleotide) as a NAD+ precursor. NAD+ declines with age, and restoring levels is hypothesized to improve mitochondrial function, DNA repair, and sirtuin activity.

The clinical evidence is early-stage. A 2024 randomized trial published in The New England Journal of Medicine has not materialized for NMN specifically, though smaller studies show NMN raises blood NAD+ levels in humans. Whether raising NAD+ translates to lifespan extension or meaningful health improvements in already-healthy individuals remains unproven. The FDA's 2022 decision to investigate NMN's regulatory status further complicates access, as the compound sits in a gray zone between supplement and investigational drug.

The HealthRX Medical Team take: NMN supplementation is not harmful at typical doses (250 to 1 to 000 mg daily), but patients should understand they are paying for a hypothesis. The compound raises a biomarker (NAD+), but the clinical outcome data connecting that rise to disease prevention or lifespan extension does not yet exist in humans.

Peptides: BPC-157, GHK-Cu, and Hexarelin

Johnson's published protocol has included several peptides. BPC-157 (Body Protection Compound) is a synthetic peptide derived from a gastric protein, studied primarily in animal models for tendon and tissue repair. GHK-Cu is a copper-binding tripeptide with wound-healing and collagen-remodeling data in cell and animal studies. Hexarelin is a growth hormone secretagogue.

None of these peptides hold FDA approval for any indication. Their inclusion in Johnson's protocol reflects access to compounding pharmacies and physician oversight. For patients, the practical concern is quality control: peptides sourced outside regulated pharmacy channels carry real risks of contamination, mislabeling, and degradation. The FDA has issued warnings about compounded peptide products repeatedly.

Testosterone: Confirmed But Context-Dependent

Johnson has confirmed testosterone optimization as part of his protocol. His approach targets physiologic ranges rather than supraphysiologic dosing, monitored through frequent labs.

Testosterone replacement in men with documented hypogonadism has well-established benefits: improved body composition, bone density, mood, and sexual function. The TRAVERSE trial, published in The New England Journal of Medicine in 2023, showed that TRT in older men with hypogonadism and cardiovascular risk factors did not increase major adverse cardiac events, addressing a long-standing safety concern.

For non-celebrity patients, the distinction matters. Johnson's testosterone use occurs within a protocol that monitors dozens of downstream biomarkers weekly. A patient receiving TRT through a standard clinic will have labs checked every 3 to 6 months. The safety profile is similar. The monitoring density is not.

What Non-Celebrity Patients Should Take from This

The dosing is not the insight. The monitoring is. Johnson's protocol works (to the extent it does) because every variable is tracked, and compounds are added or removed based on data. He discontinued rapamycin when his clocks stopped moving. Most patients on longevity compounds do not have access to monthly epigenetic testing, quarterly organ imaging, or daily physician review.

Single-compound evidence is thin. Each drug in Johnson's stack has mechanistic plausibility drawn from animal data or short-term human trials. None has been proven to extend human lifespan. Stacking unproven compounds introduces interaction risks that have never been studied in combination trials.

Cost shapes access asymmetrically. Johnson's protocol costs exceed $2 million per year. The compounds themselves are often inexpensive (acarbose is <$30/month generic; NMN runs $40 to $80/month). The expensive part is the monitoring, physician time, and compounding pharmacy access. Patients who adopt the drugs without the monitoring infrastructure are running a different experiment than Johnson is.

The HealthRX Medical Team take: Bryan Johnson's Blueprint is valuable not as a protocol to copy, but as a case study in what rigorous self-experimentation looks like, and where it still falls short. His rapamycin discontinuation demonstrates exactly the kind of evidence-responsive decision-making that longevity medicine requires. Patients interested in these compounds should start with the interventions that have the strongest safety records (acarbose, testosterone replacement for documented deficiency) and should invest in monitoring before adding speculative agents. The goal is not to replicate a billionaire's stack. It is to apply the same rigor to a smaller, evidence-proportionate protocol.

Frequently asked questions

›

References

Harrison, D.E., et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature 460, 392, 395 (2009). PubMed
Harrison, D.E., et al. "Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males." Aging Cell 13(2), 273, 282 (2014). PubMed
Longo, V.D., et al. "Interventions to slow aging in humans: Are we ready?" Aging Cell 14(4), 497, 510 (2015). PubMed
Lamming, D.W., et al. "Rapamycin: An InhibiTOR of Aging Emerges from the Soil of Easter Island." J Gerontol A 68(2), 108, 116 (2013). PubMed
Yoshino, J., et al. "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metabolism 27(3), 513, 528 (2018). PubMed
Seiwerth, S., et al. "BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing." Curr Pharm Des 24(18), 1972, 1989 (2018). PubMed
Lincoff, A.M., et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med 389, 107, 117 (2023). PubMed
Krauss, R.M., et al. "Rapamycin side-effect profile in clinical use." Drugs 75(12), 1349, 1370 (2015). PubMed